Perspectiva del analista:
La fibrosis pulmonar idiopática es una afección crónica que afecta el tejido que rodea los alvéolos de los pulmones. Se desarrolla cuando los tejidos pulmonares se vuelven rígidos y gruesos por razones desconocidas, y estos cambios dan como resultado cicatrices permanentes en los pulmones con el tiempo, lo que dificulta la respiración entre los pacientes. Actualmente, no existe una cura precisa para la fibrosis pulmonar idiopática. Tratamientos como la rehabilitación pulmonar, los medicamentos y los procedimientos quirúrgicos ralentizan el daño pulmonar y ayudan a mejorar la calidad de vida de los pacientes.
La creciente prevalencia de la fibrosis pulmonar idiopática y un número cada vez mayor de personas que fuman cigarrillos impulsan la demanda de medicamentos de tratamiento eficaces. en los próximos años. Es probable que el trabajo de investigación en curso para introducir fármacos eficaces para el tratamiento de la fibrosis pulmonar idiopática beneficie aún más al mercado en el futuro. Actualmente, el gasto en atención médica ha aumentado tanto en los mercados desarrollados como en los emergentes, lo que se espera que anime a los fabricantes en este mercado a consolidar sus esfuerzos enfocados en el desarrollo de productos nuevos e innovadores.
Descripción general del mercado:
La fibrosis es la deposición de conectivo tejido que ocurre como parte del proceso normal de curación o la deposición de exceso de tejido que ocurre como un proceso patológico. La fibrosis pulmonar idiopática afecta el tejido conectivo de los pulmones y los alvéolos (sacos de aire en los pulmones). La afección puede provocar dificultad para respirar entre las personas mientras realizan sus tareas rutinarias, que no resultan agotadoras para las personas con buena salud. El crecimiento del mercado de tratamiento de la fibrosis pulmonar idiopática se atribuye a la creciente carga de enfermedades fibróticas y al aumento del número de personas que fuman cigarrillos. Se espera que las rápidas actividades de investigación y desarrollo, que conducen a avances tecnológicos en los tratamientos, brinden oportunidades de crecimiento para el mercado de tratamiento de la fibrosis pulmonar idiopática en los próximos años.
Perspectivas estratégicas
Impulsor del mercado:
Carga creciente de la fibrosis pulmonar idiopática impulsa el mercado de tratamiento de la fibrosis pulmonar idiopática
Según datos de la Asociación Estadounidense del Pulmón, actualizados en noviembre de 2022, cada año se diagnostican aproximadamente 50 000 nuevos casos de fibrosis pulmonar idiopática en los EE. UU. Los síntomas de esta afección son más notorios en pacientes de entre 50 y 70 años. Según un artículo publicado en el British Medical Journal en septiembre de 2022, la prevalencia estimada de fibrosis pulmonar idiopática en unidades de atención especializada en 2021 fue de 36,0 por 100.000. El número de pacientes que padecen fibrosis pulmonar idiopática está aumentando en todo el mundo debido a factores de riesgo comunes como el envejecimiento, la obesidad, la presión arterial alta (hipertensión) o los antecedentes familiares, y la afección se está convirtiendo en una carga socioeconómica importante para las economías. Por lo tanto, el creciente número de pacientes con fibrosis pulmonar idiopática impulsa el crecimiento del mercado de tratamiento de enfermedades fibróticas.
Análisis segmentario:
Según el tipo de fármaco, el mercado de tratamiento de la fibrosis pulmonar idiopática se segmenta en nintedanib, pirfenidona y otros. El segmento de nintedanib tuvo una mayor participación de mercado en 2022. Se prevé que el segmento de otros registre una tasa compuesta anual más alta del 46,3% durante 2022-2030. La pirfenidona y el nintedanib son los medicamentos populares recetados para tratar enfermedades fibróticas.
Análisis regional:
América del Norte domina el mercado mundial del tratamiento de la fibrosis pulmonar idiopática. El mercado en América del Norte fue valorado en 2.362,95 millones de dólares en 2022 y se prevé que alcance los 5.527,28 millones de dólares en 2030; se espera que registre una tasa compuesta anual del 11,2% durante 2022-2030. El mercado norteamericano del tratamiento de la fibrosis pulmonar idiopática está segmentado en EE. UU., Canadá y México. La creciente carga de la fibrosis pulmonar idiopática y los avances tecnológicos en los tratamientos benefician al mercado de tratamiento de la fibrosis pulmonar idiopática en América del Norte. Los lanzamientos de productos y las iniciativas estratégicas de los actores clave del mercado también contribuyen al crecimiento del mercado. Con el creciente número de actividades de investigación y desarrollo para tratar la fibrosis pulmonar idiopática, se están introduciendo en el mercado medicamentos mejorados, lo que resulta en un mejor acceso a los medicamentos para un grupo más amplio de pacientes. Además, las amplias aprobaciones de la FDA en la región alientan a las empresas a lanzar productos tecnológicamente sofisticados.
Con la creciente prevalencia de la fibrosis pulmonar idiopática y el elevado gasto sanitario, Europa tiene la segunda mayor participación en el mercado mundial de tratamiento de enfermedades fibróticas. Se espera que Alemania domine el mercado europeo de tratamiento de la fibrosis pulmonar idiopática debido a un mejor acceso a productos y servicios tecnológicamente avanzados en el sector de la salud. Se espera que Asia Pacífico registre la CAGR más rápida en el mercado mundial de tratamiento de la fibrosis pulmonar idiopática durante 2022. 2030. El crecimiento proyectado del mercado puede atribuirse a la amplia aceptación y adopción de tecnologías de vanguardia que producen resultados precisos en un tiempo significativamente más corto. Las industrias de atención médica de toda la región están aprovechando las innovaciones en inteligencia artificial, automatización y transformación digital, impulsando la eficiencia y la productividad. profesionales médicos. La transformación en curso en diversas industrias fortalece las empresas y las economías en Asia Pacífico, permitiéndoles posicionarse como el centro de más rápido desarrollo con un enfoque dinámico y con visión de futuro para el progreso sostenible.
Análisis de actores clave:
La fibrosis pulmonar idiopática El análisis del mercado de tratamiento se basa en actores clave como Genentech, Inc. y Boehringer Ingelheim International GmbH.
Desarrollos recientes:
Las estrategias inorgánicas y orgánicas, como fusiones y adquisiciones, son altamente adoptadas por las empresas en el mercado de tratamiento de la fibrosis pulmonar idiopática. . A continuación se enumeran algunos desarrollos recientes:
En mayo de 2023, Boehringer Ingelheim inició el desarrollo clínico de BI 765423, un innovador anticuerpo inhibidor de IL-11. El estudio de fase 1 (NCT05658107) se centró en evaluar su seguridad, tolerabilidad y farmacocinética en sujetos voluntarios sanos. Los estudios preclínicos han mostrado resultados prometedores de este fármaco anti-IL-11 para inhibir y potencialmente revertir la fibrosis en varios casos fibróticos. En octubre de 2022, Boehringer Ingelheim inscribió al primer paciente estadounidense en el estudio de fase III FIBRONEER-IPF que evalúa BI 1015550. BI 1015550 es un inhibidor experimental de la fosfodiesterasa 4B (PDE4B) descubierto para el tratamiento de personas que padecen fibrosis pulmonar idiopática. El estudio forma parte del programa global FIBRONEER, que incluye dos estudios de fase III: FIBRONEER-IPF en pacientes con fibrosis pulmonar idiopática y FIBRONEER-ILD en adultos con otras enfermedades pulmonares intersticiales fibrosantes (EPI) progresivas. En septiembre de 2022, Bellerophon Therapeutics , Inc. anunció que la FDA aceptó la solicitud de reducción del tamaño del ensayo para su actual ensayo de registro REBUILD Fase 3 de INOpulse, indicado para el tratamiento de la enfermedad pulmonar intersticial fibrótica (LD). En mayo de 2022, ArisGlobal, líder mundial en soluciones de seguridad de medicamentos, adquirió la innovación digital BRASS de Boehringer Ingelheim. La adquisición permitió al primero mejorar su plataforma tecnológica LifeSphere integrando BRASS en LifeSphere Clarity. Esta integración ha contribuido al avance de la farmacovigilancia y la seguridad del paciente en toda la industria. Además, ArisGlobal ha ampliado su presencia comercial de diagnóstico clínico en varias regiones del mundo, consolidando su posición global. En marzo de 2022, Bristol Myers Squibb, una empresa farmacéutica líder, anunció la adquisición de Turning Point Therapeutics, Inc. por 76,00 dólares por acción a través de un acuerdo de fusión definitivo. Esta adquisición ha fortalecido significativamente la presencia global de Bristol Myers Squibb en el mercado farmacéutico, permitiéndole ser más proactivo a la hora de aportar innovaciones a la industria y al mismo tiempo ampliar su cartera de terapias y tratamientos que salvan vidas.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Idiopathic pulmonary fibrosis is a chronic condition that affects the tissue surrounding the alveoli in the lungs. It develops when lung tissues become stiff and thick for unknown reasons, and these changes result in permanent scarring in the lungs over time, which makes breathing difficult among patients. Currently, there is no precise cure for idiopathic pulmonary fibrosis. Treatments such as pulmonary rehabilitation, medicines, and surgical procedures slow down lung damage and help enhance the quality of patients’ lives.
The growth of the idiopathic pulmonary fibrosis treatment market is attributed to the surging burden of idiopathic pulmonary fibrosis and the increasing number of people smoking cigarettes.
The fibrotic diseases treatment market majorly consists of the players such as F. Hoffmann-La Roche Ltd; C.H. Boehringer Ingelheim International GmbH; AstraZeneca.; Bristol-Myers Squibb Company; Shionogi and Co. Ltd.; and Cipla Ltd.
The fibrotic diseases treatment market was valued at US$ 4,360.87 million in 2022.
The enteral nutrition market is expected to be valued at US$ 10,784.07 million in 2030.
The global fibrotic diseases treatment market, based on treatment, is segmented into drug type and distribution channel. Based on drug type, the idiopathic pulmonary fibrosis treatment market is segmented into nintedanib, pirfenidone, and others. The nintedanib segment held a larger market share in 2022. The others segment is anticipated to register a higher CAGR of 46.3% during 2022–2030. Pirfenidone and nintedanib are the popular medicines prescribed to treat fibrotic diseases.
By distribution channel, the global idiopathic pulmonary fibrosis treatment market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2022. The online pharmacies segment is anticipated to register the highest CAGR of 17.4% during 2022–2030.
The List of Companies - Fibrotic Diseases Treatment Market
- C.H. Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- AstraZeneca
- Shionogi and Co. Ltd.
- Cipla Ltd
- Others
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Dec 2023
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2023
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Dec 2023
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Dec 2023
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2023
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2023
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Dec 2023
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Dec 2023
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)